Explore the efficacy of the world’s first and only oral GLP-1 RA.1 See how RYBELSUS® measured up in phase 3 clinical trials.
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
In a double-blind, double-dummy trial with a primary endpoint of mean change in A1C from baseline to 26 weeks, 711 adult patients with type 2 diabetes on metformin alone or metformin with an SGLT-2i were randomized to RYBELSUS® 14 mg (n=285), liraglutide 1.8 mg subcutaneous injection (n=284), or placebo (n=142), all once daily.
Confirmatory secondary endpoint: Mean change in body weight from baseline to 26 weeks
Select secondary endpoint: Proportion of patients achieving A1C <7% at Week 26
In a double-blind, double-dummy trial with a primary endpoint of mean change in A1C from baseline to 26 weeks, 1864 adult patients with type 2 diabetes on metformin alone or metformin with a sulfonylurea were randomized to RYBELSUS® 3 mg (n=466), RYBELSUS® 7 mg (n=465), RYBELSUS® 14 mg (n=465), or Januvia® 100 mg (n=467), all once daily.
Confirmatory secondary endpoint: Mean change in body weight from baseline to 26 weeks
Select secondary endpoint: Proportion of patients achieving A1C <7% at Week 26
In an open-label trial with a primary endpoint of mean change in A1C from baseline to 26 weeks, 822 adult patients with type 2 diabetes on metformin were randomized to RYBELSUS® 14 mg (n=411) or Jardiance® 25 mg (n=410), both once daily.
Confirmatory secondary endpoint: Mean change in body weight from baseline to 26 weeks
Select secondary endpoint: Proportion of patients achieving A1C <7% at Week 26
A1C=glycated hemoglobin; CVOT=cardiovascular outcomes trial; DPP-4i=dipeptidyl peptidase-4 inhibitor; GLP-1 RA=glucagon-like peptide-1 receptor agonist; MET=metformin; SGLT-2i=sodium-glucose co-transporter-2 inhibitor.
For your patients to experience the intended efficacy of RYBELSUS®, it’s important to understand proper dosing when you prescribe.
WARNING: RISK OF THYROID C-CELL TUMORS
RYBELSUS® (semaglutide) tablets 7 mg or 14 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
WARNING: RISK OF THYROID C-CELL TUMORS
Please click here for Prescribing Information, including Boxed Warning.
References: